Grand Challenge phase 2

Challenge 3: Unusual mutation patterns

We’d like to stop cancer before it starts – prevention is better than cure. However, we don’t yet know all the individual events that can induce cancer, and we need to better understand the effects on our DNA of the cancer-causing events we already know about.

Therefore our Grand Challenge is to:


Read our science blog post all about this challenge


Certain things in the world around us, such as tobacco smoke, cause cancer. They do this by triggering chemical changes inside cells, leading to errors in the reading of the DNA genetic code.

The patterns of these DNA changes are different for each cause (or ‘carcinogen’) – almost as if they are signing their names on our genomes – and scientists can identify known carcinogens from their chemical signatures.

But there are unusual signatures whose origins we don’t know, caused in ways we haven’t yet identified. And in cancers caused by factors such as obesity, there will be many different signatures, and we don’t yet know how to pick them apart.

So in the same way that a detective uses forensic evidence from a crime scene to identify a criminal, we need to work backwards to find these cancer-causing events, to prevent the cancers they’re causing.


Dangerous levels of exposure to a carcinogen will elicit specific patterns of DNA damage, both genetic and epigenetic, that can be analysed downstream if a tumour eventually develops.

We now know that these patterns of mutation can be used as flags to work backwards to identify exposure to both known and previously unknown carcinogenic agents, and in some cases to even pinpoint the actual location of exposure.

A classic example of this is the case of aristolochic acid, which was first identified as a carcinogen after a group of Belgian women developed cancer of the upper urinary tract after eating herbs as part of a weight-loss regime. As a result it was linked to the same cancers in other regional hot spots.


This Grand Challenge seeks to use a reverse approach to conventional epidemiology, starting with the tumour’s genetic material rather than beginning with an unusual pattern of cancer incidence.

There are huge opportunities to use such an approach to untangle the multiple mutational signatures in cancers whose origins are extremely complex or multifactorial, such as those caused by lifestyle-related factors such as obesity.

Ultimately this challenge would allow us to understand the mechanisms that led from insult to mutation, identifying new prevention targets to stop, delay, or weaken their impact. And by studying the proportion of the population with these signatures (the penetrance), we might also find individual variations in DNA repair or immune response that identify people at higher risk who would benefit from more targeted intervention.


Studies identifying mutational signatures associated with tobacco smoke and ultraviolet light are ongoing, and we would like to see this approach expanded to other less-explored areas.

In addition to looking for new chemical or physical carcinogens, teams are encouraged to consider broader classes of agents that induce recognisable patterns of change in tumours.

More advanced studies might try to link other cancer-causing events such as obesity or physical inactivity to mutational or other patterns in some types of tumours, and then determine the molecular events downstream of these more complicated lifestyle-related risk factors.

We would anticipate that in addition to studies linking signatures to cancer-causing events, this challenge will require expertise in functional studies to identify the mechanisms behind these changes, which could include DNA damage repair, inflammation pathways or any number of other cellular events. Teams would benefit from collaboration between a number of biomedical disciplines in addition to cancer biology.

One of the barriers to beginning this type of study is likely to be the collection of human tissue samples, and as we appreciate that this may impact on the outlined duration of the Grand Challenge award, we encourage teams to articulate the likely timescales for this and how they would manage this requirement.

Meet the Shortlisted Teams


Stay up to date

Sign up to hear the latest news about Grand Challenge including when we open for year 2.


Is there a big problem in cancer you think we should address as part of next year's Grand Challenge? Do you have feedback on what we could do better?


We receive no Government funding for our research, so Grand Challenge is only possible thanks to people like you.

If you've been inspired to support our most ambitious funding scheme to date, you can donate today.

Text GRANDC to 70200 to donate £3




Share this page